BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology & Therapeutics 2010;31:407-14. [DOI: 10.1111/j.1365-2036.2009.04179.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Mikuriya Y, Tashiro H, Kobayashi T, Kuroda S, Abe T, Hashimoto M, Ohdan H. Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Langenbecks Arch Surg 2015;400:471-6. [PMID: 25744657 DOI: 10.1007/s00423-015-1295-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26:1195-1200. [PMID: 21410750 DOI: 10.1111/j.1440-1746.2011.06720.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
3 Xiao L, Zhang RL, Zhang H, Tulahong A, Zhang YF, Wen H, Bao YX. Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus-related and non-B, non-C hepatocellular carcinoma in Xinjiang, China. Chin J Cancer Res 2015;27:279-87. [PMID: 26157324 DOI: 10.3978/j.issn.1000-9604.2015.01.04] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013;48:405-12. [PMID: 22869157 DOI: 10.1007/s00535-012-0647-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
5 Shindo K, Maekawa S, Komatsu N, Tatsumi A, Miura M, Sato M, Suzuki Y, Matsuda S, Muraoka M, Amemiya F, Fukasawa M, Yamaguchi T, Nakayama Y, Uetake T, Inoue T, Sakamoto M, Sato T, Enomoto N. Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma. Mediators Inflamm 2015;2015:687484. [PMID: 26494948 DOI: 10.1155/2015/687484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
6 Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013-1020. [PMID: 22732513 DOI: 10.1016/j.jhep.2012.06.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 11.3] [Reference Citation Analysis]
7 Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439-1445. [PMID: 22433965 DOI: 10.1038/bjc.2012.92] [Cited by in Crossref: 209] [Cited by in F6Publishing: 216] [Article Influence: 20.9] [Reference Citation Analysis]
8 Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M. Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma: Data mining of non-HBV/non-HCV-related HCC. Hepatology Research 2011;41:564-71. [DOI: 10.1111/j.1872-034x.2011.00799.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Minami T, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K. Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma: Comparison between HBV- and HCV- related HCC. Hepatol Res 2015;45:E99-E107. [DOI: 10.1111/hepr.12468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
10 Morimoto Y, Nouso K, Wada N, Takeuchi Y, Kinugasa H, Miyahara K, Yasunaka T, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res. 2014;44:E353-E359. [PMID: 24552350 DOI: 10.1111/hepr.12315] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
11 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
12 Kobayashi S, Nouso K, Kinugasa H, Takeuchi Y, Tomoda T, Miyahara K, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma: Fucosylated hemopexin and HCC. Hepatology Research 2012;42:1187-95. [DOI: 10.1111/j.1872-034x.2012.01044.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
13 Liu C, Li L, Lu WS, Du H, Yan LN, Wen TF, Wei WR, Jiang L, Xu MQ. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization. BMC Cancer 2018;18:216. [PMID: 29466970 DOI: 10.1186/s12885-018-4121-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
14 Nouso K, Oonishi A, Wakuta A, Kariyama K. Modified radiofrequency ablation for the treatment of hepatocellular carcinoma: Modified radiofrequency ablation. Hepatol Res 2016;46:1158-61. [DOI: 10.1111/hepr.12683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, Kudo M. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84 Suppl 1:43-49. [PMID: 22156485 DOI: 10.1159/000333212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
16 Oyama A, Nouso K, Yoshimura K, Morimoto Y, Nakamura S, Onishi H, Takaki A, Iwadou S, Kariyama K, Kuwaki K, Yabushita K, Sakaguchi K, Toshimori J, Kobashi H, Moriya A, Ando M, Okada H; Okayama Hepatocellular Carcinoma Study Group. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2021;51:694-701. [PMID: 33687130 DOI: 10.1111/hepr.13633] [Reference Citation Analysis]